Twist Bioscience and Neogene Announce Broad Strategic Partnership for Next Generation Personalized T Cell Therapies

Partnership Combines Twist’s Leadership in DNA Synthesis and Synthetic Biology with Neogene’s Expertise in Personalized Engineered T Cell Therapies SOUTH SAN FRANCISCO, Calif.  and AMSTERDAM, The Netherlands – October 13, 2020 – Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and […]

Neogene Therapeutics Appoints Former Roche Chairman and Chief Executive Officer Franz B. Humer, Ph.D., as Executive Chairman of Board of Directors

Four Additional Board Members Appointed to Complement Founding Expertise NEW YORK and AMSTERDAM, October 6, 2020 – Neogene Therapeutics, Inc., a pre-clinical stage biotechnology company pioneering a new class of fully personalized neo-antigen T cell therapies to treat cancer, today announced the appointment of Franz B. Humer, Ph.D., as Executive Chairman of the Board of […]

Neogene Therapeutics Raises $110 Million Series A Financing to Develop Next-Generation Fully Personalized Neo-Antigen T Cell Receptor (TCR) Therapies

Series A Financing led by EcoR1 Capital, Jeito Capital and Syncona with continued support of strategic seed investors Vida Ventures, TPG and Two River Neogene’s proprietary technology platform identifies specific T cell receptor (TCR) genes from routine tumor samples using state-of-the-art synthetic biology tools Co-founded by renowned T cell engineering expert Ton Schumacher, Ph.D. and […]